The theme: "Reassessing Research and Clinical Practice in the Peri-pandemic Era"
This hybrid (in-person or virtual) meeting brings together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2022 Steering Committee.
Keynote Plenary: The Impact on General Mental and Addiction Care, the Socioeconomic and Political Disruption of Care, and the Change in Care; Neuropsychiatric Impact of the Infection; Implications for the Design of Future Studies
The Clinical Updates in Psychopharmacology Plenary: Insomnia; Psychosis; Multimodal Approaches to Anxiety Disorders
Venue: Fairmont Scottsdale Princess
May 31 - June 3, 2022
Scottsdale, Arizona 85255, United States